This was demonstrated by manipulating Nrf2 activity and expression in U937 human AML cells stably expressing a dominant-negative Nrf2 mutant (dnNrf2) lacking the transactivation domain and those overexpressing the wild-type Nrf2 [22]. The gene discussed is NFE2L2; the disease is acute myeloid leukemia.